| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_13d5d0ccdb4c35ecb65e5fc2e29a11f2 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y301-06008
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| filingDate |
2005-01-30^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2018-10-26^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2749b3ebb74a7b839aef2529787cd0c6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_99221acf5830ad12613edccfb2968acd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d8d6d0443c79560f9f4cbb8826cff4cc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0eaead0f55c90bd31bdab81a5ca694cc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_816e109e69afff86145e4df020a218c5 |
| publicationDate |
2018-10-26^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
ES-2687671-T3 |
| titleOfInvention |
Recombinant arylsulfatase A to reduce galatosyl sulfatide levels in a subject |
| abstract |
A recombinant arylsulfatase A formulation comprising an effective amount of a recombinant arylsulfatase A glycoform, comprising an exposed amount of mannose-6-phosphate, which enables efficient endocytosis of recombinant arylsulfatase A in vivo via the mannose pathway -6-phosphate for use in reducing levels of galactosyl sulphatide within cells within the central nervous system in a subject suffering from and / or diagnosed with metachromatic leukodystrophy, in which the formulation does not comprise any of the following: a) a vehicle for the administration of recombinant arylsulfatase A in the central nervous system, b) a component capable of causing the opening or interruption of the blood-brain barrier, and c) an intact cell, in which the formulation is suitable for systemic administration. |
| priorityDate |
2004-01-30^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |